Our analysis of gene expression data across normal prostate, primary prostate tissue, and metastatic prostate tumors revealed that while class 3 Semaphorin expression was reduced in both primary and metastatic tumors, VEGFA expression was elevated only in metastatic tumors. The gene discussed is VEGFA; the disease is metastatic neoplasm.